Top-down proteomics of saliva revealed significant changes in thymosin beta-4, defensins, and other proteins across mastocytosis subtypes, suggesting potential salivary biomarkers for this rare disease.
Non-invasive biomarkersSaliva protein analysis distinguished mastocytosis subtypes through altered thymosin beta-4 and defensin profiles
What the researchers found
Salivary proteome analysis revealed significant variations in thymosin beta-4, defensins, and other proteins between mastocytosis subtypes (cutaneous, systemic with/without skin lesions) and healthy controls.
Why it matters
Mastocytosis diagnosis typically requires invasive bone marrow biopsy. Salivary biomarkers could offer a non-invasive alternative for classification and monitoring of this rare disease.
The numbers in context
3 disease subtypes analyzed; down-regulated statherin, histatins, aPRPs; up-regulated antileukoproteinase, S100A8, thymosin beta-4
How the study worked
Top-down proteomics with label-free quantitation of saliva from patients with cutaneous mastocytosis, systemic mastocytosis (with and without cutaneous lesions), and healthy controls.
Who was studied
Mastocytosis patients (cutaneous and systemic subtypes) vs healthy controls
What this study cannot tell us
Small sample size typical for rare disease studies. Findings need validation in larger cohorts. Specificity of salivary changes to mastocytosis versus other inflammatory conditions not established.
How to read the evidence
Preliminary — small sample rare disease study with discovery-phase proteomics; requires validation.
When this study was published
Published in 2020; salivary diagnostics continue to expand for systemic disease monitoring.
The bigger picture
This study demonstrates the power of salivary proteomics for rare disease biomarker discovery, using a non-invasive sample that is easy to collect repeatedly for monitoring.
Questions still open
- Can salivary thymosin beta-4 or defensin levels distinguish mastocytosis subtypes reliably?
- Do salivary protein changes reflect disease severity or treatment response?
- Are these salivary biomarker changes specific to mastocytosis or common across myeloproliferative disorders?
Common questions
What is mastocytosis?
Why look for biomarkers in saliva?
Read the original research
Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis.
Journal of proteome research, 19(8), 3238-3253
Citation
Serrao, Simone; Firinu, Davide; Olianas, Alessandra; Deidda, Margherita; Contini, Cristina; Iavarone, Federica; Sanna, M Teresa; Boroumand, Mozhgan; Amado, Francisco; Castagnola, Massimo; Messana, Irene; Del Giacco, Stefano; Manconi, Barbara; Cabras, Tiziana. (2020). Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis.. Journal of proteome research, 19(8), 3238-3253. https://doi.org/10.1021/acs.jproteome.0c00207